BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37. [PMID: 26895767 DOI: 10.1186/s12933-016-0356-y] [Cited by in Crossref: 126] [Cited by in F6Publishing: 139] [Article Influence: 18.0] [Reference Citation Analysis]
Number Citing Articles
1 Akiyama H, Nishimura A, Morita N, Yajima T. Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol 2023;14. [DOI: 10.3389/fendo.2023.1111984] [Reference Citation Analysis]
2 Nazer R, Albratty M, Aldhahi MI, Alqurashy M, Halawi MA, Albarrati A. Effect of Dapagliflozin on Exercise Capacity and Cardiovascular Risk in Patients with Heart Failure. Healthcare 2022;10:2133. [DOI: 10.3390/healthcare10112133] [Reference Citation Analysis]
3 González-Clemente JM, García-Castillo M, Gorgojo-Martínez JJ, Jiménez A, Llorente I, Matute E, Tejera C, Izarra A, Lecube A. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy. Diabetes Ther 2022;13:1281-98. [PMID: 35687260 DOI: 10.1007/s13300-022-01280-6] [Reference Citation Analysis]
4 Song XT, Zhang PY, Fan L, Rui YF. Epicardial adipose tissue and right ventricular function in type 2 diabetes mellitus using two-dimensional speckle tracking echocardiography. Diab Vasc Dis Res 2022;19:14791641221118622. [PMID: 35999047 DOI: 10.1177/14791641221118622] [Reference Citation Analysis]
5 Karlstaedt A, Taegtmeyer H. Cardio-Onco-Metabolism - Metabolic vulnerabilities in cancer and the heart. J Mol Cell Cardiol 2022;171:71-80. [PMID: 35777454 DOI: 10.1016/j.yjmcc.2022.06.008] [Reference Citation Analysis]
6 Berezin AE, Berezin AA. Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes? EMJ. [DOI: 10.33590/emj/22-00026] [Reference Citation Analysis]
7 Wu QL, Zheng T, Li SZ, Chen JA, Xie ZC, Lai JM, Zeng JY, Lin JT, Huang JS, Lin MH. Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr 2022;14:41. [PMID: 35272683 DOI: 10.1186/s13098-022-00810-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 2022. [PMID: 35210595 DOI: 10.1038/s41591-022-01707-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
9 Raphael DM, Mogella AH, Mtalemwa EE, Kabuka B. Dapagliflozin and Spironolactone Improved Clinical Symptoms and CV Outcomes in Patient with HF Preserved Ejection Fraction (HFpEF) in Hard-to-Reach Rural African Population: A Case Series. CRCM 2022;11:465-473. [DOI: 10.4236/crcm.2022.1111064] [Reference Citation Analysis]
10 Afzal M, Al-Abbasi FA, Nadeem MS, Alshehri S, Ghoneim MM, Imam SS, Almalki WH, Kazmi I. Sodium-Glucose Cotransporter-2 Inhibitors Improve Cardiovascular Dysfunction in Type 2 Diabetic East Asians. Metabolites 2021;11:794. [PMID: 34822452 DOI: 10.3390/metabo11110794] [Reference Citation Analysis]
11 Egocheaga I, Escobar C, Pallarés V, Obaya JC. [Dapagliflozin in the prevention and treatment of heart failure]. Semergen 2021;47 Suppl 1:11-7. [PMID: 34785155 DOI: 10.1016/j.semerg.2021.10.001] [Reference Citation Analysis]
12 Del Vecchio L, Beretta A, Jovane C, Peiti S, Genovesi S. A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease. Drugs 2021;81:1491-511. [PMID: 34363606 DOI: 10.1007/s40265-021-01573-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, Wittbrodt ET, Fenici P, Kosiborod M, Mauricio D, Franch-Nadal J. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol 2021;20:139. [PMID: 34243779 DOI: 10.1186/s12933-021-01323-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Yandrapalli S, Malik A, Horblitt A, Pemmasani G, Aronow WS, Frishman WH. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2. Cardiol Rev 2020;28:219-35. [PMID: 32271194 DOI: 10.1097/CRD.0000000000000311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Lee KW, Devaraj NK, Ching SM, Veettil SK, Hoo FK, Deuraseh I, Soo MJ. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials. Oman Med J 2021;36:e273. [PMID: 34239714 DOI: 10.5001/omj.2021.62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chazova IE, Shestakova MV, Zhernakova YV, Blinova NV, Markova TN, Mazurina NV, Ezhov MV, Tereshchenko SN, Zhirov IV, Komarov AL, Mironova OY, Yuricheva YA, Suhareva OY, Kislyak OA, Mkrtumyan AM, Podzolkov VI, Azizov VA, Zelveyan PA, Grigorenko EA, Rahimov ZY, Sarybaev AS, Kasymova SD, Narzullaeva AR. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Evrazijskij kardiologičeskij žurnal 2021. [DOI: 10.38109/2225-1685-2021-2-6-61] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Idzerda NMA, Stefansson BV, Pena MJ, Sjostrom DC, Wheeler DC, Heerspink HJL. Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers. Nephrol Dial Transplant 2020;35:1570-6. [PMID: 31005993 DOI: 10.1093/ndt/gfz064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
18 Kuchay MS, Farooqui KJ, Mishra SK, Mithal A. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Adv Exp Med Biol 2021;1307:213-30. [PMID: 32006266 DOI: 10.1007/5584_2020_479] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
19 Russian Society of Cardiology (RSC) (. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol 2020;25:4083. [DOI: 10.15829/1560-4071-2020-4083] [Cited by in Crossref: 89] [Cited by in F6Publishing: 98] [Article Influence: 29.7] [Reference Citation Analysis]
20 Yin D, Hui Y, Yang C, Xu Y. Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes: Study protocol of a randomized controlled trial. Medicine (Baltimore) 2020;99:e22660. [PMID: 33031329 DOI: 10.1097/MD.0000000000022660] [Reference Citation Analysis]
21 Tereshchenko SN, Zhirov IV, Uskach TM, Saidova MA, Golitsyn SP, Gupalo EM, Nasonova SN, Narusov OY, Safiullina AA, Tereshchenko AS, Stukalova OV. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Evrazijskij kardiologičeskij žurnal 2020. [DOI: 10.38109/2225-1685-2020-3-6-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
22 Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556-77. [PMID: 32855502 DOI: 10.1038/s41574-020-0392-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 30.0] [Reference Citation Analysis]
23 Chiang CE, Ueng KC, Chao TH, Lin TH, Wu YJ, Wang KL, Sung SH, Yeh HI, Li YH, Liu PY, Chang KC, Shyu KG, Huang JL, Tsai CD, Hung HF, Liu ME, Chao TF, Cheng SM, Cheng HM, Chu PH, Yin WH, Wu YW, Chen WJ, Lai WT, Lin SJ, Yeh SJ, Hwang JJ. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. J Chin Med Assoc 2020;83:587-621. [PMID: 32628427 DOI: 10.1097/JCMA.0000000000000359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
24 Triantakonstanti VV, Toskas A, Iordanidis NS, Andreou T, Koftis TV, Gallos JK. Pivaloyl-protected glucosyl iodide as a glucosyl donor for the preparation of β-C-glucosides. Tetrahedron Letters 2020;61:152173. [DOI: 10.1016/j.tetlet.2020.152173] [Reference Citation Analysis]
25 Mehta A, Bhattacharya S, Estep J, Faiman C. Diabetes and Heart Failure: A Marriage of Inconvenience. Clin Geriatr Med 2020;36:447-55. [PMID: 32586474 DOI: 10.1016/j.cger.2020.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
26 Acuna SA, Dossa F, Baxter N. Meta-analysis of noninferiority and equivalence trials: ignoring trial design leads to differing and possibly misleading conclusions. J Clin Epidemiol 2020;127:134-41. [PMID: 32540386 DOI: 10.1016/j.jclinepi.2020.05.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovasc Diabetol 2020;19:87. [PMID: 32534590 DOI: 10.1186/s12933-020-01067-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
28 Viswanathan V, Singh KP. Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT). Diabetes Technol Ther 2019;21:415-22. [PMID: 31339784 DOI: 10.1089/dia.2019.0052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019;40:1447-67. [PMID: 31050706 DOI: 10.1210/er.2018-00141] [Cited by in Crossref: 115] [Cited by in F6Publishing: 121] [Article Influence: 38.3] [Reference Citation Analysis]
30 Chung IM, Rajakumar G, Subramanian U, Venkidasamy B, Khanna VG, Thiruvengadam M. Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications: An overview. Biotechnol Appl Biochem 2020;67:920-8. [PMID: 31736194 DOI: 10.1002/bab.1853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
31 Clapham JC. Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now? Methods Mol Biol 2020;2076:1-30. [PMID: 31586319 DOI: 10.1007/978-1-4939-9882-1_1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
32 Kim JH, Ko HY, Wang HJ, Lee H, Yun M, Kang ES. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. Diabetes Obes Metab 2020;22:373-82. [PMID: 31692240 DOI: 10.1111/dom.13905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
33 Avgerinos I, Liakos A, Tsapas A, Bekiari E. Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin. Diabetes Metab Syndr Obes 2019;12:2549-57. [PMID: 31819580 DOI: 10.2147/DMSO.S190356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Sato K, Mano T, Iwata A, Toda T. Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study. J Clin Pharmacol 2019. [PMID: 31792991 DOI: 10.1002/jcph.1561] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
35 Zainordin NA, Hatta SFWM, Mohamed Shah FZ, Rahman TA, Ismail N, Ismail Z, Abdul Ghani R. Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED). J Endocr Soc 2020;4:bvz017. [PMID: 31993550 DOI: 10.1210/jendso/bvz017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
36 Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124:121-141. [PMID: 30605420 DOI: 10.1161/circresaha.118.311371] [Cited by in Crossref: 258] [Cited by in F6Publishing: 274] [Article Influence: 64.5] [Reference Citation Analysis]
37 Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs 2019;79:1135-46. [PMID: 31236801 DOI: 10.1007/s40265-019-01148-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
38 Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res 2018;122:1439-59. [PMID: 29748368 DOI: 10.1161/CIRCRESAHA.117.311588] [Cited by in Crossref: 171] [Cited by in F6Publishing: 181] [Article Influence: 42.8] [Reference Citation Analysis]
39 Gill A, Gray SP, Jandeleit-dahm KA, Watson AM. SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus. CDR 2019;15:349-56. [DOI: 10.2174/1573399814666180417121246] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-miranda J, Tybjærg-hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. CVP 2019;17:515-37. [DOI: 10.2174/1570161117666190503123911] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
41 Mkrtumyan AM, Markova TN, Mishchenko NK. Analysis of cardiovascular safety of novel glucose-lowering medications. Kardiologiia 2019;59:76-83. [DOI: 10.18087/cardio.2019.7.10267] [Reference Citation Analysis]
42 Berezin AE, Berezin AA. Impaired function of fibroblast growth factor 23 / Klotho protein axis in prediabetes and diabetes mellitus: Promising predictor of cardiovascular risk. Diabetes Metab Syndr 2019;13:2549-56. [PMID: 31405675 DOI: 10.1016/j.dsx.2019.07.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
43 Bhuiyan MMR, Begum A. Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018. Obesity Medicine 2019;14:100099. [DOI: 10.1016/j.obmed.2019.100099] [Reference Citation Analysis]
44 Díaz-Rodríguez E, Agra RM, Fernández ÁL, Adrio B, García-Caballero T, González-Juanatey JR, Eiras S. Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 2018;114:336-46. [PMID: 29016744 DOI: 10.1093/cvr/cvx186] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 22.0] [Reference Citation Analysis]
45 Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab 2019;17:e84353. [PMID: 31372172 DOI: 10.5812/ijem.84353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
46 Triantakonstanti VV, Andreou T, Koftis TV, Gallos JK. Synthesis of ertugliflozin from d-glucose. Tetrahedron Letters 2019;60:994-6. [DOI: 10.1016/j.tetlet.2019.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sinha B, Ghosal S. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis. Diabetes Ther 2019;10:891-9. [PMID: 30875065 DOI: 10.1007/s13300-019-0597-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
48 Landgraf R, Kellerer M, Aberle J, Fach E, Gallwitz B, Hamann A, Joost H, Klein H, Müller-wieland D, Nauck MA, Reuter H, Schreiber S, Siegel E. Therapie des Typ-2-Diabetes. Diabetologe 2019;15:146-67. [DOI: 10.1007/s11428-019-0459-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE. The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions. Heart Fail Rev 2018;23:303-23. [PMID: 29516230 DOI: 10.1007/s10741-018-9685-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
50 Dey AK, Groenendyk J, Mehta NN, Gourgari E. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes. Clin Cardiol 2019;42:406-12. [PMID: 30635924 DOI: 10.1002/clc.23152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
51 Singh AK, Unnikrishnan AG, Zargar AH, Kumar A, Das AK, Saboo B, Sinha B, Gangopadhyay KK, Talwalkar PG, Ghosal S, Kalra S, Joshi S, Sharma SK, Sriram U, Mohan V. Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians. Diabetes Ther 2019;10:393-428. [PMID: 30706366 DOI: 10.1007/s13300-019-0562-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
52 Baruah MP, Makkar BM, Ghatnatti VB, Mandal K. Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control. Indian J Endocrinol Metab 2019;23:140-9. [PMID: 31016169 DOI: 10.4103/ijem.IJEM_160_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Kumar S, Talwalkar PG, Das S, Goswami S. Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus. Indian J Endocrinol Metab 2019;23:150-8. [PMID: 31016170 DOI: 10.4103/ijem.IJEM_161_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Akkuş O, Akkuş G, Kaypaklı O. The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus. Endocr Metab Immune Disord Drug Targets 2019;19:207-13. [PMID: 30569879 DOI: 10.2174/1871530319666181218121508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
55 Stapff MP. Using real world data to assess cardiovascular outcomes of two antidiabetic treatment classes. World J Diabetes 2018; 9(12): 252-257 [PMID: 30588287 DOI: 10.4239/wjd.v9.i12.252] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
56 Galli M, D'Amario D, Sofia C, Vaccarella M, Crea F, Aspromonte N. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opin Drug Metab Toxicol 2018;14:1273-85. [PMID: 30472914 DOI: 10.1080/17425255.2018.1551360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Shah SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in patients with concurrent diabetes mellitus using glucose lowering drugs. Expert Rev Clin Pharmacol 2019;12:45-52. [PMID: 30488734 DOI: 10.1080/17512433.2019.1552830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
58 Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol 2018;17:144. [PMID: 30447687 DOI: 10.1186/s12933-018-0790-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 15.8] [Reference Citation Analysis]
59 Dalan R. Sodium-Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus: A Review of Large-Scale Cardiovascular Outcome Studies and Possible Mechanisms of Benefit. Cardiol Rev 2018;26:312-20. [PMID: 29608505 DOI: 10.1097/CRD.0000000000000201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
60 Ng KM, Lau YM, Dhandhania V, Cai ZJ, Lee YK, Lai WH, Tse HF, Siu CW. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes. Sci Rep 2018;8:14872. [PMID: 30291295 DOI: 10.1038/s41598-018-33293-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
61 Zelniker TA, Braunwald E. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes. Journal of the American College of Cardiology 2018;72:1845-55. [DOI: 10.1016/j.jacc.2018.06.040] [Cited by in Crossref: 132] [Cited by in F6Publishing: 137] [Article Influence: 26.4] [Reference Citation Analysis]
62 Kobalava ZD, Kiyakbaev GК. TYPE 2 DIABETES AND CARDIOVASCULAR COMPLICATIONS: IS IT POSSIBLE TO IMPROVE PROGNOSIS BY GLUCOSE LOWERING THERAPY? Russ J Cardiol 2018. [DOI: 10.15829/1560-4071-2018-8-79-91] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
63 Pancholia AK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Indian Heart J 2018;70:915-21. [PMID: 30580866 DOI: 10.1016/j.ihj.2018.08.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
64 Triantakonstanti VV, Mountanea OG, Papoulidou KC, Andreou T, Koftis TV, Gallos JK. Studies towards the synthesis of ertugliflozin from l-Arabinose. Tetrahedron 2018;74:5700-8. [DOI: 10.1016/j.tet.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Llano A, Mckay G. The treatment of type 2 diabetes in heart failure. Pract Diab 2018;35:123-6. [DOI: 10.1002/pdi.2178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
66 Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol 2019;234:223-30. [DOI: 10.1002/jcp.26851] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 12.8] [Reference Citation Analysis]
67 Molina-vega M, Muñoz-garach A, Fernández-garcía JC, Tinahones FJ. The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert Opinion on Drug Safety 2018;17:815-24. [DOI: 10.1080/14740338.2018.1497158] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
68 Zhuang XD, He X, Yang DY, Guo Y, He JG, Xiao HP, Liao XX. Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials. Cardiovasc Diabetol 2018;17:79. [PMID: 29871636 DOI: 10.1186/s12933-018-0722-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
69 Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, McGuire DK, Wilding JP, Gause-Nilsson IA, Langkilde AM, Johansson PA, Sabatine MS. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J 2018;200:83-9. [PMID: 29898853 DOI: 10.1016/j.ahj.2018.01.012] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 18.4] [Reference Citation Analysis]
70 Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Gause‐nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD. DECLARE‐TIMI 58: Participants’ baseline characteristics. Diabetes Obes Metab 2018;20:1102-10. [DOI: 10.1111/dom.13217] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 16.4] [Reference Citation Analysis]
71 Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24:73-79. [PMID: 27898586 DOI: 10.1097/med.0000000000000311] [Cited by in Crossref: 54] [Cited by in F6Publishing: 107] [Article Influence: 10.8] [Reference Citation Analysis]
72 Tong L, Adler S. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. Postgrad Med 2018;130:381-93. [PMID: 29667921 DOI: 10.1080/00325481.2018.1457397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
73 Gallwitz B. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data. Eur Endocrinol 2018;14:17-23. [PMID: 29922347 DOI: 10.17925/EE.2018.14.1.17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
74 Guo M, Ding J, Li J, Wang J, Zhang T, Liu C, Huang W, Long Y, Gao C, Xu Y. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab 2018;20:1977-82. [PMID: 29573118 DOI: 10.1111/dom.13295] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 8.0] [Reference Citation Analysis]
75 Gorenek B, Boriani G, Dan G, Fauchier L, Fenelon G, Huang H, Kudaiberdieva G, Lip GYH, Mahajan R, Potpara T, Ramirez JD, Vos MA, Marin F, Blomstrom-lundqvist C, Rinaldi A, Bongiorni MG, Sciaraffia E, Nielsen JC, Lewalter T, Zhang S, Gutiérrez O, Fuenmayor A; ESC Scientific Document Group. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). EP Europace 2018;20:895-6. [DOI: 10.1093/europace/euy051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sesti G, Antonelli Incalzi R, Bonora E, Consoli A, Giaccari A, Maggi S, Paolisso G, Purrello F, Vendemiale G, Ferrara N. Management of diabetes in older adults. Nutrition, Metabolism and Cardiovascular Diseases 2018;28:206-18. [DOI: 10.1016/j.numecd.2017.11.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
77 Kuo GH, Gaul MD, Liang Y, Xu JZ, Du F, Hornby P, Xu G, Qi J, Wallace N, Lee S, Grant E, Murray WV, Demarest K. Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors. Bioorg Med Chem Lett. 2018;28:1182-1187. [PMID: 29523385 DOI: 10.1016/j.bmcl.2018.02.057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
78 Avogaro A, Delgado E, Lingvay I. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev 2018;34:e2981. [PMID: 29320602 DOI: 10.1002/dmrr.2981] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
79 Pioli MR, Ritter AMV, Modolo R. Unsweetening the Heart: Possible Pleiotropic Effects of SGLT2 Inhibitors on Cardio and Cerebrovascular Alterations in Resistant Hypertensive Subjects. Am J Hypertens 2018;31:274-80. [PMID: 29186300 DOI: 10.1093/ajh/hpx204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
80 . Type 2 diabetes: glycaemic control. Practical Diabetes Care 2018. [DOI: 10.1002/9781119052210.ch10] [Reference Citation Analysis]
81 Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, Okabe M. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17:6. [PMID: 29301516 DOI: 10.1186/s12933-017-0658-8] [Cited by in Crossref: 160] [Cited by in F6Publishing: 172] [Article Influence: 32.0] [Reference Citation Analysis]
82 Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park K, Seufert J, Kang ES, Sternthal E, Karagiannis A, Mantzoros CS. Pharmacotherapy of type 2 diabetes: An update. Metabolism 2018;78:13-42. [DOI: 10.1016/j.metabol.2017.08.010] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 21.8] [Reference Citation Analysis]
83 She L, Wu H. Meta-Analysis on Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus. YM 2018;02:129-145. [DOI: 10.4236/ym.2018.23014] [Reference Citation Analysis]
84 Khalimov YS, Agafonov PV, Kuzmich VG. ROLE AND PLACE OF DAPAGLIFLOZIN IN THE MANAGEMENT OF 2nd TYPE DIABETES: FROM THEORY TO PRACTICE. Medicinskij sovet 2017. [DOI: 10.21518/2079-701x-2017-3-22-30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
85 Schernthaner G, Khunti K, Lotan C, Burnier M, Drexel H, Prázný M. Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D). Ther Clin Risk Manag 2017;13:1569-76. [PMID: 29276388 DOI: 10.2147/TCRM.S144362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
86 Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: are they safe? Postgrad Med. 2018;130:72-82. [PMID: 29039237 DOI: 10.1080/00325481.2018.1394152] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
87 Schernthaner G, Lehmann R, Prázný M, Czupryniak L, Ducena K, Fasching P, Janež A, Karasik A, Kempler P, Martinka E, Shestakova MV, Duvnjak LS, Tankova T. Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol 2017;16:137. [PMID: 29061170 DOI: 10.1186/s12933-017-0622-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
88 Scheen AJ. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Rev Clin Pharmacol 2017;10:1303-16. [PMID: 28984487 DOI: 10.1080/17512433.2017.1389645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
89 Saleem F. Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus. Cureus. 2017;9:e1751. [PMID: 29226041 DOI: 10.7759/cureus.1751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
90 Scheen AJ. Pharmacological management of type 2 diabetes: what's new in 2017? Expert Rev Clin Pharmacol 2017;10:1383-94. [PMID: 28879786 DOI: 10.1080/17512433.2017.1376652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
91 Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 2018;20:344-51. [PMID: 28771923 DOI: 10.1111/dom.13077] [Cited by in Crossref: 132] [Cited by in F6Publishing: 140] [Article Influence: 22.0] [Reference Citation Analysis]
92 Fioretto P, Mansfield TA, Ptaszynska A, Yavin Y, Johnsson E, Parikh S. Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs Aging 2016;33:511-22. [PMID: 27357173 DOI: 10.1007/s40266-016-0382-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
93 Nakatsu Y, Kokubo H, Bumdelger B, Yoshizumi M, Yamamotoya T, Matsunaga Y, Ueda K, Inoue Y, Inoue MK, Fujishiro M, Kushiyama A, Ono H, Sakoda H, Asano T. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Int J Mol Sci. 2017;18. [PMID: 28777298 DOI: 10.3390/ijms18081704] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
94 Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 2017;5:709-17. [PMID: 28781064 DOI: 10.1016/S2213-8587(17)30258-9] [Cited by in Crossref: 227] [Cited by in F6Publishing: 240] [Article Influence: 37.8] [Reference Citation Analysis]
95 Jabbour S. Durability of response to dapagliflozin: a review of long-term efficacy and safety. Curr Med Res Opin 2017;33:1685-96. [PMID: 28699798 DOI: 10.1080/03007995.2017.1354822] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
96 Gautam S, Agiro A, Barron J, Power T, Weisman H, White J. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol 2017;16:93. [PMID: 28756774 DOI: 10.1186/s12933-017-0575-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
97 Yu H, Woo VC. Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin. Diabetes Metab Syndr Obes 2017;10:317-32. [PMID: 28769579 DOI: 10.2147/DMSO.S117982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
98 Katsiki N, Purrello F, Tsioufis C, Mikhailidis DP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 2017;18:1243-60. [DOI: 10.1080/14656566.2017.1351946] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
99 Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017;25:262-284. [PMID: 28178565 DOI: 10.1016/j.cmet.2016.12.022] [Cited by in Crossref: 630] [Cited by in F6Publishing: 650] [Article Influence: 105.0] [Reference Citation Analysis]
100 Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol 2017;16:84. [PMID: 28683796 DOI: 10.1186/s12933-017-0564-0] [Cited by in Crossref: 134] [Cited by in F6Publishing: 143] [Article Influence: 22.3] [Reference Citation Analysis]
101 Sharma DC, Asirvatham A, Singh P. Dose Modification of Antidiabetic Agents in Patients with Type 2 Diabetes Mellitus and Heart Failure. Indian J Endocrinol Metab 2017;21:618-29. [PMID: 28670548 DOI: 10.4103/ijem.IJEM_442_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
102 DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab. 2017;19:1353-1362. [PMID: 28432726 DOI: 10.1111/dom.12982] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 15.2] [Reference Citation Analysis]
103 Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab 2017;19:1276-88. [PMID: 28345814 DOI: 10.1111/dom.12954] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
104 Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017;16:65. [PMID: 28511711 DOI: 10.1186/s12933-017-0547-1] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
105 Ji Q. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists. Clin Ther. 2017;39:1244-1264. [PMID: 28526416 DOI: 10.1016/j.clinthera.2017.03.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
106 Bonnet F, Scheen AJ. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. Diabetes Metab 2017;43:299-313. [PMID: 28522196 DOI: 10.1016/j.diabet.2017.04.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
107 Scheen AJ. Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol 2017;13:583-92. [PMID: 28374622 DOI: 10.1080/17425255.2017.1315102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
108 Dey J. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus. Postgrad Med 2017;129:409-20. [PMID: 28322073 DOI: 10.1080/00325481.2017.1307081] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
109 Fioretto P, Avogaro A. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother 2017;18:517-27. [PMID: 28277831 DOI: 10.1080/14656566.2017.1300253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
110 Petrykiv S, Sjöström CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Clin J Am Soc Nephrol 2017;12:751-9. [PMID: 28302903 DOI: 10.2215/CJN.10180916] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 15.8] [Reference Citation Analysis]
111 Disse E. Études LEADER et EMPA-REG OUTCOME : implications en pratique clinique. Médecine des Maladies Métaboliques 2017;11:2S49-2S55. [DOI: 10.1016/s1957-2557(17)30057-3] [Reference Citation Analysis]
112 Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol 2017;16:29. [PMID: 28241822 DOI: 10.1186/s12933-017-0511-0] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
113 Kosiborod M, Gause-Nilsson I, Xu J, Sonesson C, Johnsson E. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure. J Diabetes Complications 2017;31:1215-21. [PMID: 28284707 DOI: 10.1016/j.jdiacomp.2017.02.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
114 Bays HE, Sartipy P, Xu J, Sjöström CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol 2017;11:450-458.e1. [PMID: 28502502 DOI: 10.1016/j.jacl.2017.01.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
115 Singh AK, Singh R. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs. Expert Rev Clin Pharmacol 2017;10:429-42. [PMID: 28121469 DOI: 10.1080/17512433.2017.1287562] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
116 Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovasc Diabetol. 2017;16:18. [PMID: 28148253 DOI: 10.1186/s12933-017-0499-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
117 Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. Hypertens Res 2017;40:535-40. [DOI: 10.1038/hr.2016.193] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
118 Schernthaner G, Jarvis S, Lotan C, Prázný M, Wanner C, Wascher TC. Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes. Ther Clin Risk Manag 2017;13:69-79. [PMID: 28144148 DOI: 10.2147/TCRM.S121804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
119 Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, Ohara M, Yamamoto T, Ito Y, Hirano T. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 2017;16:8. [PMID: 28086872 DOI: 10.1186/s12933-016-0491-5] [Cited by in Crossref: 84] [Cited by in F6Publishing: 94] [Article Influence: 14.0] [Reference Citation Analysis]
120 Kostev K, Pscherer S, Rist R, Busch S, Scheerer MF. Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study. J Diabetes Sci Technol 2017;11:590-6. [PMID: 28300454 DOI: 10.1177/1932296816688011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
121 Nasrallah MP, Abi Khalil C, Refaat MM. The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis. BioMed Research International 2017;2017:1-15. [DOI: 10.1155/2017/9257930] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Imprialos KP, Boutari C, Stavropoulos K, Doumas M, Karagiannis AI. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psychiatry 2017;88:249-53. [DOI: 10.1136/jnnp-2016-314704] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
123 Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166125. [PMID: 27835680 DOI: 10.1371/journal.pone.0166125] [Cited by in Crossref: 130] [Cited by in F6Publishing: 140] [Article Influence: 18.6] [Reference Citation Analysis]
124 Dalama B, Mesa J. Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. Revista Española de Cardiología 2016;69:1088-97. [DOI: 10.1016/j.recesp.2016.07.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
125 Lim LL, Tan AT, Moses K, Rajadhyaksha V, Chan SP. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype. J Diabetes Complications 2017;31:494-503. [PMID: 27866701 DOI: 10.1016/j.jdiacomp.2016.10.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
126 Dalama B, Mesa J. New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. Rev Esp Cardiol (Engl Ed) 2016;69:1088-97. [PMID: 27687335 DOI: 10.1016/j.rec.2016.07.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
127 Luconi M, Raimondi L, Di Franco A, Mannucci E. Which is the main molecular target responsible for the cardiovascular benefits in the EMPA-REG OUTCOME trial? A journey through the kidney, the heart and other interesting places. Nutr Metab Cardiovasc Dis 2016;26:1071-8. [PMID: 27776917 DOI: 10.1016/j.numecd.2016.09.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
128 Oral EA. Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond. Drugs Context 2016;5:212299. [PMID: 27648101 DOI: 10.7573/dic.212299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
129 Salsali A, Kim G, Woerle HJ, Broedl UC, Hantel S. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab 2016;18:1034-40. [PMID: 27376831 DOI: 10.1111/dom.12734] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
130 Katsiki N, Athyros VG, Mikhailidis DP. Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions. Current Medical Research and Opinion 2016;32:1513-4. [DOI: 10.1080/03007995.2016.1201465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
131 Kvapil M. Antidiabetic drugs of interest. Interní Med 2016;18:125-129. [DOI: 10.36290/int.2016.036] [Reference Citation Analysis]
132 Kraakman MJ, Dragoljevic D, Kammoun HL, Murphy AJ. Is the risk of cardiovascular disease altered with anti-inflammatory therapies? Insights from rheumatoid arthritis. Clin Transl Immunology 2016;5:e84. [PMID: 27350883 DOI: 10.1038/cti.2016.31] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
133 Leiter LA, Cefalu WT, de Bruin TWA, Xu J, Parikh S, Johnsson E, Gause-nilsson I. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab 2016;18:766-74. [DOI: 10.1111/dom.12666] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
134 Steinberg HO. Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. Postgrad Med 2016;128:398-408. [PMID: 26999348 DOI: 10.1080/00325481.2016.1168687] [Reference Citation Analysis]
135 Johnsson K, Johnsson E, Mansfield TA, Yavin Y, Ptaszynska A, Parikh SJ. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med 2016;128:346-55. [PMID: 26878357 DOI: 10.1080/00325481.2016.1153941] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
136 Ramanujan S, Gadkar K, Kadambi A. Quantitative Systems Pharmacology: Applications and Adoption in Drug Development. Systems Pharmacology and Pharmacodynamics 2016. [DOI: 10.1007/978-3-319-44534-2_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]